Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;384(1):1-12.
doi: 10.1007/s00441-020-03364-w. Epub 2021 Jan 12.

The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity

Huanrong Lan #  1 , Qi Xue #  2 , Yuyao Liu  3 , Ketao Jin  3 , Xingliang Fang  4 , Hong Shao  5
Affiliations
Review

The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity

Huanrong Lan et al. Cell Tissue Res. 2021 Apr.

Abstract

Mesenchymal stem cell (MSC)-based tissue regeneration therapy has been extensively investigated for cardiac regeneration over the past two decades. Numerous animal and clinical investigations demonstrated the efficacy of various types of MSCs towards myocardial protection and restoration against anthracycline-induced cardiotoxicity (AIC). It has been established that local or systemic administration of MSCs considerably improved the cardiac function, while ameliorating inflammatory responses and myocardial fibrosis. Several factors influence the outcomes of MSC treatment for AIC, including MSC types, dosages, and routes and duration of administration. In this review, we discuss the recent (from 2015 to 2020) experimental and clinical research on the preventive and regeneration efficacy of different types of MSCs (with or without supporting agents) against AIC, as well as the key factors responsible for MSC-mediated cardiac repair. In addition, challenges and future perspectives of MSC-based cardiac regeneration therapy are also outlined.

Keywords: Anthracycline-induced cardiotoxicity; Cardiac regeneration; Cardioprotectant; Doxorubicin; Mesenchymal stem cells.

PubMed Disclaimer

References

    1. A. Soliman N, Abd-Allah SH, Hussein S, Alaa Eldeen M et al (2017) Factors enhancing the migration and the homing of mesenchymal stem cells in experimentally induced cardiotoxicity in rats. IUBMB Life 69:162–169. https://doi.org/10.1002/iub.1600 - DOI - PubMed
    1. Abd Allah SH, Hussein S, Hasan MM et al (2017) Functional and structural assessment of the effect of human umbilical cord blood mesenchymal stem cells in doxorubicin-induced cardiotoxicity. J Cell Biochem 118:3119–3129. https://doi.org/10.1002/jcb.26168 - DOI - PubMed
    1. Abushouk AI, Muhammad A, Salem A et al (2019) Mesenchymal stem cell therapy for doxorubicin-induced cardiomyopathy : potential mechanisms, governing factors, and implications of the heart stem cell debate. Front Pharmacol 10:635. https://doi.org/10.3389/fphar.2019.00635 - DOI - PubMed - PMC
    1. Al-Abd AM, Mahmoud AM, El-Sherbiny GA et al (2011) Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44:591–601. https://doi.org/10.1111/j.1365-2184.2011.00783.x - DOI - PubMed - PMC
    1. Al-Shabanah OA, El-Kashef HA, Badary OA et al (2000) Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacol Res 41:31–37. https://doi.org/10.1006/phrs.1999.0568 - DOI - PubMed

MeSH terms

LinkOut - more resources